Co-Diagnostics Inc
NASDAQ:CODX

Watchlist Manager
Co-Diagnostics Inc Logo
Co-Diagnostics Inc
NASDAQ:CODX
Watchlist
Price: 3.055 USD 1.83%
Market Cap: 6.4m USD

Gross Margin

34%
Current
Declining
by 25%
vs 3-y average of 59.1%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
34%
=
Gross Profit
$172.8k
/
Revenue
$507.9k

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
34%
=
Gross Profit
$172.8k
/
Revenue
$507.9k

Peer Comparison

Country Company Market Cap Gross
Margin
US
Co-Diagnostics Inc
NASDAQ:CODX
6.3m USD
Loading...
US
Abbott Laboratories
NYSE:ABT
212.2B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
187.9B USD
Loading...
US
Stryker Corp
NYSE:SYK
137.5B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
136B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
128.4B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
49.4B EUR
Loading...
US
Becton Dickinson and Co
NYSE:BDX
58B USD
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
54.9B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
48.5B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.1B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in the United States of America
Percentile
37th
Based on 12 729 companies
37th percentile
34%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

Co-Diagnostics Inc
Glance View

Market Cap
6.4m USD
Industry
Health Care

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 101 full-time employees. The company went IPO on 2017-07-12. The firm is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. The company also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The firm uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

CODX Intrinsic Value
Not Available
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
34%
=
Gross Profit
$172.8k
/
Revenue
$507.9k
What is Co-Diagnostics Inc's current Gross Margin?

The current Gross Margin for Co-Diagnostics Inc is 34%, which is below its 3-year median of 59.1%.

How has Gross Margin changed over time?

Over the last 3 years, Co-Diagnostics Inc’s Gross Margin has decreased from 86% to 34%. During this period, it reached a low of 34% on Oct 30, 2025 and a high of 86% on Aug 30, 2022.

Back to Top